A Pfizer-BioNTech COVID-19 vaccine trial for children aged between five and 11 has produced "positive results" and has shown a "robust immune response", the two firms have said.
Full ArticlePfizer COVID vaccine trial for children aged under 12 shows 'robust immune response'
Sky News
0 shares
2 views
You might like
Related news coverage
High hopes for Ebola vaccine after trial shows strong immune response
Children and adults have shown a strong immune response to a possible Ebola vaccine during clinical trials in Sierra Leone.
Sky News
BioNTech/Pfizer Covid vaccine triggers ‘robust’ response in younger children
Companies say data provide ‘strong foundation’ to seek authorisation to vaccinate those aged 5 to 11
FT.com